Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

Isomorphic Labs Series C at $40-50B Valuation — Alphabet’s AI Drug Discovery Spinoff Attracts International Capital as Application Layer Commands Premium While Infrastructure Investors Retreat

by Team Lumida
October 8, 2026
in AI
Reading Time: 7 mins read
A A
0
Isomorphic Labs Series C at $40-50B Valuation — Alphabet’s AI Drug Discovery Spinoff Attracts International Capital as Application Layer Commands Premium While Infrastructure Investors Retreat
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Isomorphic Labs Series C valuation $40-50 billion (vs $2.1 billion Series B just 5 months prior) validates 19-24x valuation jump in 5 months, marking extreme capital concentration into AI drug discovery/life sciences applications. Google DeepMind spinoff founded 2021 on AlphaFold protein-folding breakthrough; Demis Hassabis (DeepMind co-founder, now Alphabet chief scientist) leading. Partnerships with Eli Lilly and Novartis on cancer and immune disorder drug discovery. External investors: Thrive Capital (early OpenAI backer), Singapore/UAE/UK sovereign wealth funds. Hassabis goal: reduce drug discovery from years to months. Critical timing: Isomorphic Series C at $40-50B same day as Firmus infrastructure IPO collapse (Oct 8), validating bifurcated capital flows. Application-layer investors (biotech, life sciences, pharma) chasing AI at premium valuations despite infrastructure investors baling. Pattern validates Hayes thesis but with crucial modification: capex cycle peaking at infrastructure layer, but application layer (drug discovery, life sciences, biotech) still in early innings, attracting fresh capital at escalating valuations.
  • Pharmaceutical partnership validation signals biotech confidence in AI ROI independent of infrastructure uncertainty. Eli Lilly and Novartis partnerships represent major pharma betting on AI drug discovery reducing clinical trial timelines and development costs. Unlike data center infrastructure with 7-8 year payback and binary demand uncertainty, pharmaceutical applications have clear regulatory pathways (FDA approval), established customer economics (pharma margins 60-70%), and measurable endpoints (molecules, clinical trial outcomes). Consequence: biotech/pharma AI application investors pricing for success independent of infrastructure capex skepticism. If Isomorphic delivers first FDA-approved AI-discovered drug 2027-2028 (Hassabis timeline), validates application-layer ROI and supports $40-50B valuation. Risk: if AI drug discovery stalls or faces regulatory delays, massive valuation compression for entire biotech AI sector. But current investor appetite suggests confidence in regulatory/pharma pathway.
  • Capital source bifurcation (SWFs, Thrive vs institutional venture) validates geopolitical + strategic capital flows. Singapore, UAE, UK SWFs participating in Series C = strategic capital from wealth funds prioritizing AI strategic assets. SWF participation typically indicates government/sovereign positioning for long-term strategic value (drug discovery, biotech independence) vs short-term financial return. Thrive Capital early OpenAI backer = signals AI application investors recycling prior OpenAI returns into next frontier (life sciences). Contrast: Firmus IPO failed because retail/institutional equity capital retreated on valuations; Isomorphic attracting SWF + strategic capital unconcerned with valuation multiples if strategic benefit clear. Pattern: traditional VC/PE + institutional capital retreating on infrastructure; SWF + strategic capital advancing on applications. Implication: capital markets bifurcating by investor type (financial vs strategic) and by AI use case (infrastructure vs applications).
  • Valuation trajectory ($2.1B → $40-50B in 5 months) validates venture/biotech capital cycles decoupling from infrastructure capex cycle. Traditional pattern: infrastructure capex peak → margin compression → capital rotation to applications. But Isomorphic trajectory suggests applications already in premium capital phase independent of infrastructure cycle. Alphabet managing capital allocation: (1) Waymo self-driving raised at $126B (Feb 2026), (2) Isomorphic $40-50B (Oct 2026), (3) both “Other Bets” opened to outside investors. Strategy: Alphabet deploying infrastructure capex (data centers for training) while spinning out application vehicles (Waymo, Isomorphic) for external capital at premium valuations. If successful, Alphabet captures infrastructure economics + application upside without balance sheet strain. Risk: if applications (Waymo autonomous driving, Isomorphic drug discovery) face execution headwinds or regulatory delay, $126B + $40-50B valuations face severe compression. But current capital flow suggests Alphabet + strategic investors confident in execution timelines.

What Happened?

Isomorphic Labs, a London-based artificial intelligence drug discovery company spun out of Google DeepMind in 2021, is in early-stage financing talks to raise new capital at a valuation of at least $40 billion, with potential valuation reaching $50 billion according to people familiar with the matter. The valuation represents a dramatic increase from the company’s Series B funding round completed just five months prior, when Isomorphic raised $2.1 billion. The financing round has not closed and terms could change. Isomorphic Labs is led by Demis Hassabis, who co-founded DeepMind and recently transitioned to the role of Alphabet’s chief scientist while remaining the company’s head. The company has announced partnerships with major pharmaceutical firms Eli Lilly & Co. and Novartis AG to collaborate on drug discovery focused on cancer and immune disorders. External investors backing Isomorphic include Thrive Capital (an early backer of OpenAI), and sovereign wealth funds from Singapore, the United Arab Emirates, and the United Kingdom. Isomorphic Labs is competing with other artificial intelligence developers attempting to apply advanced models to life sciences research, including OpenAI, which released a life sciences research model in 2026. Hassabis has stated the company’s objective is to reduce drug discovery timelines from years to a matter of months.

Why It Matters?

Isomorphic Labs’ $40-50 billion valuation represents a critical bifurcation in artificial intelligence capital flows: while infrastructure investors are retreating from premium valuations (Firmus Grid’s Australian IPO collapsed on the same day), application-layer investors—particularly in biotech and pharmaceutical drug discovery—are aggressively deploying capital at escalating multiples. The Series C valuation jump from $2.1 billion to $40-50 billion in five months ($19-24x increase) reflects investor confidence that artificial intelligence drug discovery represents a fundamentally different risk profile from infrastructure plays. Unlike data center capacity, which faces binary demand uncertainty and 7-8 year payback periods, pharmaceutical applications have established regulatory pathways (FDA approval processes), proven customer economics (pharmaceutical margins of 60-70%), and measurable success metrics (approved drugs, clinical trial outcomes). The participation of sovereign wealth funds from Singapore, the UAE, and the UK alongside Thrive Capital signals strategic capital positioning for long-term artificial intelligence competitive advantages in biotech rather than short-term financial returns. Alphabet’s strategy of spinning out high-valuation application companies (Waymo at $126 billion, Isomorphic at $40-50 billion) while managing infrastructure capex internally suggests confidence that the near-term AI opportunity lies in applications rather than infrastructure buildout. However, the valuation carries execution risk: if Isomorphic or other AI drug discovery platforms face regulatory delays or fail to deliver FDA-approved drugs within the promised timelines, valuations could face severe compression across the entire biotech AI sector.

What’s Next?

Monitor Isomorphic drug discovery pipeline: if company announces first human clinical trials or IND applications in 2027 (validates Hassabis timeline), supports $40-50B valuation; if clinical development stalls or faces regulatory pushback, signals valuation compression. Watch Eli Lilly and Novartis deployment of Isomorphic AI models: if major pharma reports measurable acceleration in drug discovery or candidate molecule generation (validates application ROI), supports biotech AI valuations; if partnerships disappoint or stall, threatens Isomorphic narrative. Track other AI drug discovery funding rounds: if additional players raise at similarly aggressive valuations (validates application-layer capital wave), confirms biotech AI bifurcation from infrastructure skepticism; if rounds disappoint or valuations compress, suggests Isomorphic being repriced lower. Most critically, monitor FDA approval timelines for AI-discovered drugs: first FDA approval of molecule originally discovered by AI would validate 40-year drug discovery acceleration narrative and likely trigger sector-wide repricing upward. Conversely, regulatory delays or failed clinical trials would trigger biotech AI valuation implosion. Watch Alphabet investor expectations: if equity markets price Isomorphic/Waymo at premium to public comps, suggests market recognizes application-layer separation from infrastructure cycle; if market increasingly skeptical of spinout strategy, signals bifurcation thesis breaking down. Finally, track SWF participation in follow-on rounds: if Singapore/UAE/UK SWFs continue aggressive biotech AI participation (validates strategic capital positioning), supports multi-year application-layer capital wave independent of infrastructure cycle.

Affected Tickers and Coins: GOOGL | LLY | NOVN | OpenAI (private)

Source: Bloomberg

Previous Post

Goldman Sachs Warns AI Shift Leaves Middle Managers in Limbo — Organizational Restructuring Validates Scope of Automation Beyond Infrastructure, Signals Talent Concentration Risk and Wage Pressure as Pyramid Career Structures Collapse

Next Post

Crude Jumps 5.2% on Houthi Attacks and Gulf Shut-Ins as Stocks Retreat From Records

Recommended For You

China’s Military Is ‘Actively Soliciting’ Nvidia’s Most Advanced Chips for AI-Enabled Military Capabilities, a Congressional Commission Says in Its 2026 Report

by Team Lumida
4 hours ago

A congressional commission said China’s military is seeking advanced Nvidia chips and evading export controls, including via data centers in Malaysia.

Read more

Bipartisan Push to Attach AI Chip Export Limits to the December NDAA Gains Steam After the Huang Affair, With Schumer, Jeffries and Speaker Johnson Backing the AI Overwatch, MATCH and Chip Security Acts

by Team Lumida
12 hours ago

Lawmakers from both parties are pushing three chip export bills into the December defense bill after Jensen Huang’s resignation, but time is short.

Read more

Banks Pause a $480 Million Nvidia GPU Loan to Aolani Cloud Tied to ByteDance After New US Licensing Rules for Malaysia and Singapore Data Centers

by Team Lumida
1 day ago
ByteDance Is Buying Custom Chips From Taiwan Because It Cannot Buy Nvidia’s, Which US Rules Permit

Banks paused or reconsidered a $480 million Aolani Cloud loan for Nvidia GPUs tied to ByteDance after new US licensing rules, Bloomberg reported.

Read more

Commerce and Justice Say They Began Investigating Nvidia Partner Megaspeed in 2024, as Critics Ask Why It Kept Getting Chips After Nvidia’s ‘No Sell’ Listing

by Team Lumida
2 days ago

Commerce and Justice said they opened export-control probes into Megaspeed in 2024 and inspected it in June 2025, as critics question how it kept buying chips.

Read more

Nvidia Warns Chip Buyers That the Remote Access Security Act Could Expose Them to US ‘Legal Action’ and Caps Sales to Clouds Renting Over 50% of GPUs to Chinese Firms

by Team Lumida
2 days ago

Nvidia cautioned customers that the proposed Remote Access Security Act could bring US legal action over Chinese cloud access to its chips, CNBC reported.

Read more

Anthropic’s IPO Could Hand 300-Plus Investors a Windfall, With a $1.33 Trillion Valuation About 38% Above Its $965 Billion May Round

by Team Lumida
2 days ago

Anthropic’s IPO, expected to value it at $1.33 trillion or more, is set to reward over 300 investors, from Spark and Menlo to Amazon and Alphabet.

Read more

Commerce Moves to Close the Offshore Data-Center Loophole for Chinese AI Firms and Requires Licenses for Chip Exports to Five Countries, Its First Policy Response to the Nvidia Scandal

by Team Lumida
2 days ago

Commerce issued a rule curbing Chinese firms’ offshore access to Nvidia compute and requiring chip-export licenses for five higher-risk countries.

Read more

Trump Administration Plans to Name Nvidia, OpenAI and More Than Two Dozen AI Firms ‘National Champions’ as the BAI AI ETF Sits 33% Below Its June Record

by Team Lumida
3 days ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

The Trump administration plans to name more than two dozen AI firms, including Nvidia and OpenAI, US national champions, the WSJ reported.

Read more

OpenAI Launches ChatGPT Wallet With Amex, Mastercard and Visa, Letting ‘Dots’ Agents Buy for U.S. Pro Subscribers

by Team Lumida
5 days ago

OpenAI launched ChatGPT Wallet with American Express, Mastercard and Visa, letting its “dots” agents make purchases for U.S. Pro subscribers over 18.

Read more

OpenAI’s Quarterly Revenue Tops $10 Billion for the First Time, Up Nearly 50% in a Quarter, as Anthropic’s Growth Slows to About 47%

by Team Lumida
1 week ago

OpenAI’s third-quarter revenue hit $10 billion for the first time, up nearly 50% from the prior quarter, as Anthropic’s growth slowed, Bloomberg reports.

Read more
Next Post
Crude Jumps 5.2% on Houthi Attacks and Gulf Shut-Ins as Stocks Retreat From Records

Crude Jumps 5.2% on Houthi Attacks and Gulf Shut-Ins as Stocks Retreat From Records

Samsung Guides to a Quarter Worth More Than All of 2025 and the Stock Falls, While a Loss-Making Data Centre Firm Rises

Samsung Guides to a Quarter Worth More Than All of 2025 and the Stock Falls, While a Loss-Making Data Centre Firm Rises

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a close up of a pile of crypt coins

Tether CEO Paolo Ardoino Discusses the Stablecoin Giant’s Profitable Business and Controversies

April 7, 2025
Vietnam Maintains 8% Growth Target Despite Tariff Challenges and Global Uncertainty

Vietnam Maintains 8% Growth Target Despite Tariff Challenges and Global Uncertainty

May 5, 2025
Luxury Brands Struggle as U.S. and China Falter, Emerging Markets Fail to Fill the Gap

Luxury Brands Struggle as U.S. and China Falter, Emerging Markets Fail to Fill the Gap

May 16, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018